Delfi Diagnostics: Amoolya Singh
Amoolya Singh has been named chief technology officer of cancer liquid biopsy firm Delfi Diagnostics. She joins the company from Grail, where she was senior VP of data science and CSO. Prior to that, she was head of discovery technologies at Calico, Alphabet's drug discovery company, and VP of R&D at Amyris. Singh holds a Ph.D. in computational biology and an M.S. in computer science from the University of California, Berkeley, and a B.S. in biology and computer science from Carnegie Mellon University. She also completed postdoctoral fellowships at the European Molecular Biology Laboratory (EMBL) in Heidelberg, Germany, and at Emory University and worked as a software engineer at various companies.
AcuamarkDx: Tim Gordon, Chiara Gabbi
Acuamark Diagnostics (AcuamarkDx), an early cancer detection company, has added Tim Gordon and Chiara Gabbi to its board of directors.
Gordon has 40 years of experience at Ernst & Young in audit and financial advisory services for both US-based and global health and life sciences companies. He is a graduate of Harvard Business School's Advanced Management Program.
Gabbi is a physician-scientist with more than 20 years of experience in clinical and translational medicine in metabolic diseases, hepatology, cancer, personalized medicine, and genomics. She holds a Ph.D. in medical science from Karolinska Institutet, an M.D. with specialization in internal medicine from the University of Modena and Reggio Emilia, and a certificate in clinical research from Harvard Medical School.
Exai Bio: Karen Knudsen
Exai Bio, a company developing RNA and AI-enabled liquid biopsy for early cancer detection, has appointed Karen Knudsen to its board of directors. Knudsen is the former CEO of the American Cancer Society and its affiliate, the American Cancer Society Cancer Action Network. Prior to leading ACS, Knudsen served as executive VP of oncology services and enterprise director of the Sidney Kimmel Comprehensive Cancer Center at Jefferson Health. She also served as president of the Association of American Cancer Institutes and was a member of the National Cancer Institute's board of scientific advisers.
Evotec: Craig Johnstone
Craig Johnstone will step down as chief operating officer of Evotec, effective Dec. 31. The company did not provide a reason for his departure. Johnstone joined the German firm in 2012 as senior VP of drug discovery and innovation efficiency and became COO and a member of the management board in 2019. His responsibilities will be distributed internally until a new organization structure is designed, in line with Evotec's strategic review.
Watchmaker Genomics: Scott Gotshall
Watchmaker Genomics has appointed Scott Gotshall as general counsel. Gotshall was previously CEO and general counsel at Personal Genome Diagnostics, where he also previously served as head of business management. Gotshall also previously worked at Roche Diagnostics, where he provided legal support for molecular diagnostics, sequencing, and custom biotech. He later led the strategic contracting team for the entire diagnostics portfolio.
For additional recent items on executive appointments, promotions, and departures in the omics and molecular diagnostics space, please see the People in the News page on our website.